Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.

European journal of haematology - 1 Feb 2025

Shacham-Abulafia Adi, Volcheck Yulia, Ellis Martin, Shapira Shirley, Tavor Sigal, Gourevitch Anna, Kreiniz Natalia, Stanevski Anfisa, Raanani Pia, Koren-Michowitz Maya

Abstract excerpt

OBJECTIVES: Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation. METHODS: This retrospective analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Niacinamide

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Treatment Outcome

Source

Identifiers

PMID: 39433446
DOI: 10.1111/ejh.14330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.PMID 39433446Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Semantic proximity Read ↗

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.Semantic proximity Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

Asciminib as a third line option in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Semantic proximity Read ↗

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.